Angus Liu is a Senior Staff Writer for Fierce Pharma, specializing in biopharma news and developments. With a background in journalism from Medill School of Journalism, Angus covers topics such as regulatory updates, drug launches, clinical trials, and industry trends. His work has been featured in Fierce Biotech as well, showcasing his expertise in the biotechnology sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
Angus Liu's coverage predominantly focuses on the healthcare and pharmaceutical industry. His articles reflect a strong emphasis on drug development, FDA approvals, clinical trials, and specific medications within the pharmaceutical industry.
Given this focus, Angus would likely be receptive to pitches from experts who have in-depth knowledge of drug development processes or regulatory affairs in the pharmaceutical industry. Pitches offering insights into recent clinical trial outcomes or FDA announcements related to new drugs may also capture his interest.
Sources with access to relevant data or those involved in government announcements pertaining to healthcare regulation could also provide valuable perspectives for Angus's coverage. It is important for potential sources to offer fact-based analysis and credible commentary that aligns with the themes covered in Angus's articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Angus Liu
Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an accelerated approval filing for a kidney disease candidate.
By: Angus Liu
As expected, Novartis' radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024.
By: Angus Liu
Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis' Scemblix has won an accelerated approval to treat newly diagnosed patients.
By: Angus Liu
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker.
By: Angus Liu
Baxter International plans to exit China's intravenous fluids market, multiple local media outlets report, citing a letter to distributors.
By: Angus Liu
Bristol Myers' $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company's ongoing efficiency push.
By: Angus Liu
AstraZeneca executives past and present are under investigation in China. GSK is paying $300 million upfront to obtain a T-cell engager to develop for autoimmune diseases.
By: Angus Liu
An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry.
By: Angus Liu
As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors.
By: Angus Liu
Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial.
(833) 317-6278 
